Φορτώνει......
miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1
BACKGROUND: Treatment options for metastatic castrate-resistant prostate cancer (mCRPC) are limited and typically are centered on docetaxel-based chemotherapy. We previously reported that elevated miR-375 levels were significantly associated with poor overall survival of mCRPC patients. In this stud...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Mol Cancer |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5105253/ https://ncbi.nlm.nih.gov/pubmed/27832783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-016-0556-9 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|